GILD · News · 20260804N
Veklury Sales Decline
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 76 · Surprise 100 · In source text
Second-quarter Veklury sales declined 81% year over year. The decline reduced growth in total product sales to 8%, versus 10% growth for product sales excluding Veklury. Gilead lowered its full-year 2026 forecast for Veklury because of the sharp quarterly sales contraction.
Key facts
- Gilead posted an 81% drop in Veklury (Covid-19 treatment) sales during the second quarter, prompting a lowered full-year forecast for Veklury. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Gilead posted an 81% drop in Veklury (Covid-19 treatment) sales during the second quarter, prompting a lowered full-year forecast for… |
| revenue | negative | probable | — | Gilead posted an 81% drop in Veklury (Covid-19 treatment) sales during the second quarter, prompting a lowered full-year forecast for… |